Cytovation

Cytovation is a clinical stage immuno-oncology biotech developing first-in-class immunotherapies. CyPep-1, its lead asset, is a synthetic peptide engineered to selectively target tumor cells. CyPep-1 has a unique dual MoA applicable across solid tumors: (1) direct tumor-specific membrane lysis and in-situ vaccination, combined with (2) immune activation through inhibition of the -catenin pathway. Building on strong FIH clinical data, Cytovation is advancing CyPep-1 to POC/pivotal clinical development with a focus on b-catenin-driven cancers

Biotech,oncology,and immuno-oncology

Cytovation operates in the Biotechnology research industry.

Cytovation's revenue is 11m - 100m

Cytovation has 11 - 50 employees.